Cantor Fitzgerald began coverage on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note published on Monday morning, BenzingaRatingsTable reports. The firm issued a neutral rating and a $8.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, August 1st. Cowen set a $5.00 price objective on Adamas Pharmaceuticals and gave the company a hold rating in a research note on Friday, August 9th. HC Wainwright reduced their price objective on Adamas Pharmaceuticals from $40.00 to $30.00 and set a buy rating on the stock in a research note on Tuesday, May 28th. Evercore ISI reiterated a buy rating and issued a $55.00 price objective on shares of Adamas Pharmaceuticals in a research note on Monday, August 12th. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $20.43.

Shares of NASDAQ ADMS opened at $6.02 on Monday. The stock has a market cap of $168.85 million, a P/E ratio of -1.24 and a beta of 1.62. The company has a current ratio of 7.27, a quick ratio of 7.05 and a debt-to-equity ratio of 3.05. Adamas Pharmaceuticals has a 12-month low of $4.20 and a 12-month high of $23.25. The business’s fifty day simple moving average is $6.11 and its 200-day simple moving average is $6.40.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.08. The business had revenue of $12.69 million for the quarter, compared to analysts’ expectations of $12.62 million. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. On average, equities analysts forecast that Adamas Pharmaceuticals will post -3.74 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Alps Advisors Inc. increased its holdings in Adamas Pharmaceuticals by 4.5% in the first quarter. Alps Advisors Inc. now owns 66,026 shares of the specialty pharmaceutical company’s stock valued at $469,000 after buying an additional 2,860 shares during the last quarter. Advisor Group Inc. increased its holdings in Adamas Pharmaceuticals by 53.4% in the second quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 3,900 shares during the last quarter. Quantamental Technologies LLC purchased a new position in shares of Adamas Pharmaceuticals during the second quarter worth about $25,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Adamas Pharmaceuticals by 10.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 46,928 shares of the specialty pharmaceutical company’s stock worth $291,000 after purchasing an additional 4,381 shares during the last quarter. Finally, BNP Paribas Arbitrage SA purchased a new position in shares of Adamas Pharmaceuticals during the first quarter worth about $33,000. 63.44% of the stock is currently owned by hedge funds and other institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Further Reading: Why does a company issue an IPO?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.